Evaluation of Efficacy, Tolerability, and Treatment Satisfaction with Almotriptan in 3 Consecutive Migraine Attacks

Abstract

The objective of the open-label, multicenter Migraine – Satisfaction with Treatment: Reality with Almogran® study was to assess efficacy, tolerability, and satisfaction with almotriptan 12.5 mg among migraineurs who were not achieving adequate results with their current acute therapy. Data from 434 patients (342 evaluable), were obtained for 929 attacks by 154 neurologists in France. Using a questionnaire developed by the National Agency for Accreditation and Evaluation in Health (ANAES), almotriptan was associated with an increased proportion of patients experiencing significant relief at 2 h (69.3 vs. 26.6%), tolerating the medication well (91.2 vs. 76.0%), able to resume activities (70.5 vs. 24.9%), and taking only 1 dose (59.4 vs. 28.1%) compared with previous therapies. At 2 h, headache pain had disappeared in 33.4% of attacks and was mild in 26.9%. Recurrence rate was 28.4% and rescue analgesics were used in 20.9% of attacks. The rate of adverse event-related discontinuations was 2.6%. The proportion of patients who were very satisfied/satisfied overall with almotriptan treatment was 69%. Almotriptan 12.5 mg was effective, well-tolerated and associated with a high rate of treatment satisfaction in patients whose previous acute migraine therapy was inadequate according to the ANAES recommendations.

The GRIM2005 Study of Migraine Consultation in France II. Psychological Factors Associated with Treatment Response to Acute Headache Therapy and Satisfaction in Migraine

“…The internal consistency of the resolved structure, as measured by Cronbach's á coefficient, was 0.83. Data on the factorial structure of the Brief COPE in the study sample will be presented elsewhere (16).…”

Treatment Satisfaction Instruments for Different Purposes during a Productʼs Lifecycle

“…[49] Treatment satisfaction was found to be predictive of treatment continuation. [43] High levels of treatment satisfaction appeared to be reflective of improvements in patients' QOL and functional status, [51] with satisfaction on the Patient Perception of Migraine Questionnaire (PPMQ) associated with patients' ability to return to normal or mildly impaired functioning more quickly. For example, a patient's score on the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) was significantly associated with the severity of erectile dysfunction, [44] while reduced treatment satisfaction was significantly associated with the number of tolerability issues in diabetes patients.…”

“…Internal consistency; construct validity (discriminant, convergent, known groups); test-retest reliability; responsiveness; both anchor-based and distribution-based methods were used in the calculation of MID A meaningful between-group difference was Focus on within-person change over time a calculated to compare patient satisfaction between treatment groups [12] a Receiver operative characteristic curve analysis was used to identify a cut-off value able to differentiate satisfied and unsatisfied patients who could benefit from switching therapy [10] a Factors associated with treatment satisfaction Adherence; [42] side effects/tolerability; [43] efficacy and symptom control; [44] functional status; [45] quality of life [46] Productivity [47] a Socioeconomic status; [48] a patient-provider communication [49] a a Different characteristics for treatment satisfaction instruments that have been developed for different purposes.…”

Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example

“…1 Intensity of headache pain and migraine-associated symptoms at time of treatment with almotriptan 12.5 mg for 500 patients in the German postmarketing surveillance study for whom data on 3 attacks were available [28] Fig. 2 Physicians' global assessment of efficacy and tolerability and patients' overall assessment of treatment satisfaction from the German postmarketing surveillance study [28] Severe pain Postmarketing surveillance study conducted in France: MISTRAL The MIgraine -Satisfaction with Treatment: Reality with ALmogran (MISTRAL) was an open-label, multicentre study of almotriptan 12.5 mg conducted in France that assessed efficacy, tolerability and patient satisfaction among migraineurs with a long history of migraine who were dissatisfied with their current acute therapy [29]. Data from 434 patients (342 evaluable for efficacy), 57.6% of whom had been using a triptan, were obtained for 929 attacks (up to 3 consecutive attacks/patient) by 154 neurologists.…”